Taiho Pharmaceutical Obtains Rights To Cancer Drug Yondelis From Spanish PharmaMar
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Japanese drug maker Taiho Pharmaceutical March 31 signed a license agreement with Spain's PharmaMar SA on anticancer compound Yondelis (trabectedin). According to the agreement, Taiho obtained exclusive rights to develop and market in Japan. PharmMar receives an initial payment of ¥1 billion, as well as future payments and sales royalties in Japan. Taiho will also cover all development and marketing costs of Yondelis in Japan. Taiho is planning to start Phase I trials for Yondelis to treat soft tissue sarcoma and cervical cancer in Japan. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.